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Vascular endothelial growth factor is a powerful 
mitogen for endothelial cells, recently reported to be 
produced by keratinocytes. In the present work, we 
examined human keratinocytes in primary culture 
for the splice variants of vascular endothelial growth 
factor. III situ hybridization revealed that 100% of 
cultured human keratinocytes expressed l11.RNA for 
this cytokine, and analysis by reverse transcriptase-
polymerase chain reaction indicated that three spe-
cies of mRNA were produced. Southern hybridiza-
tion and size calculations of peR products revealed 
mRNA species corresponding to 121, 165, and 189 
amino-acid forms of this cytokine. Using a rabbit 
R ecently, a new fami ly of secreted growth factors capable of directly stimu lating endothelial cell pl'O-liferation was discovered [1] . Members of this f.1mi ly have been referred to variously as vascul ar permeability factor [2-5], vascu lar endothelial 
growth factor (VEGF) [6-9], and vascu lotropin [10] , but molecular 
cloning has shown that all are derived from the same gene [1 ,4,9]. 
VEGF is a heparin-binding glycoprotein [11] occurring in four 
molecular forms that contain 121 (VEGF I 2 1) , 165 (VEGF I6S)' 189 
(VEGF I 89), or 206 (VEGF2116) amino acids, generated by altemative 
RNA splicing [1,12]. Only the two smaller forms, VEGF I 2 1 and 
VEGF t65 , are secreted, appearing as disulfide-linked dimers with a 
molecular weight of approximately 36-45 kDa. By contrast, 
VEGF 1H9 and VEGF206 remain cell-associated [12]. 
Substantial data have documented production of VEGF proteins 
by tumor cell lines and tumor tissues [1,3,13-16], and their 
expression has been studied by ill sitll hybridization and Northern 
blot analysis i.n normal tissues [16] , corpus lu teum [17], and the 
developing brain [18] . However, Little is known about the produc-
tion and secretion of VEGF by primary, untransform ed celJs in 
culture. 
Human keratinocytes are known to produce an array of cytokines 
t1lat, among other efFects, can act dircctly or indirectly on endo-
thelial cells (e.g., interleukin-1 a: and -6, tumor necrosis f.1cto r-a:, 
and transforming grow til factor-ex and - (3 [19]). Recently, Brown el 
al [20] reported that rat and guinea pig keratinocytes express VEGF 
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growth Wctor. 
anti-vascular endothelial growth factor antiserum, 
we radioimmunoprecipitated two molecular weight 
forms (approximately 45 and 58 kDa, non-reducing 
conditions) from keratinocyte culture supernatants. 
Under reducing conditions, three bands of approxi-
mately 15, 20, and 24 kDa appeared, corresponding 
with the predominant forms of vascular endothelial 
growth factor described. We propose that secretion 
of vascular endothelial growth factor by human ke-
ratinocytes ill vi"o sustains angiogenesis during phys-
iologic tissue repair and in pathologic states accom-
panied by neovascularization. Key lVords: allgioge"esis/ 
ski". ] I""est Del'matoi 104:7-10, 1995 
mRNA dlll'illg wound healing and in tissue culture, and they 
mentioned that human keratinocytes secrete VEGF. We now 
report the production of VEGF by cultlll'cd pl;mary human kera-
tinocytes at thc protein and nucleic acid .l evels and the biochemical 
characterization of keratinocyte-derived VEGF. 
MATERlALS AND METHODS 
Cell Culture Normal human kcratinocytcs were obtaincd fro m Promo-
Cell (Heidelberg, Germany) and were maintained at 37°C in 5% CO2 in 
serum-free kcratinocyte growth medium (promoCell) , which consists of 
MCD B 153 supplemcnted with 0.4% bovine pituitary cxtract, 0.1 ng/ ml 
recombinant cpidcnllal growth factor,S p,g/ ml insulin , 0.5 p,g/ ml hydro-
cortisonc, and amphotericin B/gentamicin . The human epidermoid carci-
noma ccll line A431 was maintained in R.PMI-1 640 with 10% fctal bovinc 
scrum and 1. % penicillin /streptomycin solu tion (GmCO BRL, Gaithers-
burg, MD). 
For ;11 .1;11/ hybridi za tion , keratinocytes werc grown 011 eight-wcll Lab-
Tek chamber slides (Nunc, R oskilde , Denmark). After bcing washed in 
phosphate-bufrercd sa line, the cells were fixed in frcshly preparcd 4% 
paraformaldchyde in phosphate-bufFered saline (20 min , room tempera-
ture). rinsed twice in phosphatc-bufFercd sa line, dc hydrated in serial alco-
hols, and stored at -20· C until further use . 
r" Situ Hybridization We used ill S;( II hybridi za tion protocol described 
by Mueller el nl [21) , with minor alterations. T he plasmid pKS-VEGF
' 2 1 
f14) was digcsted with appropliate restriction cnzymes (BamHl for T7 and 
EcoRl for T3) to obtain sense and antisensc c1~A probes by ;11 !Jilm 
transcription with T3 and T7 RNA polymel'ases, respectively, as described 
by thc manuf.1cturer (Boehringer Mallnheim , Vicnna , Austria). Before ill 
S;(II hybridization , fixed keratinocytes, as dcscribed above, were rehydrated, 
digested with protcinase K (1 p,g/ ml ill 100 mM Tris, pH 8.0, and 50 111M 
ethylcnediaminetetra-acetic acid [EDTAJ) , and rcfixed in 4% paraformal-
dehyde. Subsequcntly, slides wcrc incubated for 10 tr\in in a solution of 0.1 
M triethano laminc hydrochloridc (pH 8.0) containing fres hly added 0.25% 
acetic anhydride, dehydrated in serial alcohols, and air dried. For hyblid-
ization, cells were ovcrlaid with the hybridization bufFcr (4 X saline-sodium 
citratc bufFcr [SSC). 20 mM phosphatc bufFer, 10% dcxtran sulfate. 1 X 
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Figure 1. Schematic representation of VEGF mRN~ species. A : 
Positiolls of oligonucleotide primers (alTOI/IS) and probcs (bors) arc indica ted 
for VEGF2 06 ' B: The four poss iblc splice variants ofVEGF. 
Dcnhardt's solu tion, 1 mM EDT A, 50% formamidc, 100 J-Lg/ml dcna turcd 
salmon spcrm DNA, 100 J-Lg/ml poly (A) , 100 J-Lg / ml yeast tRNA, and 0.10;') 
dithiothreitol) containing the ;/1 Ili/ro transcribed 35S_labelcd VEGF antisensc 
or sense RNA probc (3 X 106 cpm/ l00 J-LI). Slides were then mounted with 
coverslips, sealed with rubber cement, and incubated for 18 h at SO· C. Aftcr 
removal ofthc covcrslips, slidcs wcrc washcd twice in 50% fonnalnide/2 X 
SSC/1 mM EDTA for 20 min at 54°C , once in 2 X SSC at room 
tcmperaturc, foUowed by an incubation with RNAse A (20 J-Lg/ ml) and 
RNAse Tl (1 U/ ml) in 2 X SSC/l mM EDTA for 30 min at 37° C. 
Specimens wcre then washcd twice in 50% form amide/2 X SSC for 20 min 
at 54°C, rinsed in 2 X SSC, dehydrated through graded alcohol, and a ir 
dricd. For autoradiography, slides were dipped in pho tographic emulsion 
(Ilford KS, 1:2 with 2% glycero l) and kept in light-tight boxes for 4 weeks 
at 4°e. Finally, slides were develop cd with Kodak D19, fixed, a nd 
counter stained with hematoxylin. Cells were visualized by differentia l 
interference-contras t or dark-fi eld microscopy. 
RNA Polymerase Chain Reaction (PCR) To prepare RNA, 1 X 1.07 
cell s were grown in 7S-cm2 pe tri di shes for 16 h as described above to 80')1. 
confluency. RNA was cxtracted with RNAzol (C INNAIB iotecx Lab., ln c., 
Houston, TX) according to the manufacturer's instructions, with the 
addition of two extractioll steps with phenol-chloroform-isoamylalcobol 
(25:24:1) and chloroform-isoamylalcohol (24:1), fo llowcd by precipi tatio n 
with isopropanol. T he pellct was dri cd under vacuum for 10 min, dissolve d 
in H 2 0 , and storcd at - 70°e. To gencra te cDNA. 2 J-Lg of RNA (in 10.5 
J-Ll dH20) was reverse-transcribed using Supersc ript RNasc H - rC verse 
transcriptase (RT) (Gibco BRL) and oligo-dT ,s (Boehringer Mannheim). 
cDNA was ampli fied lIsing 0.5 J-LM of each sense (S' -CCA TGA ACT TTC 
TGC TGT CTT-3') and antiscnse primer (S'-TCG ATC GTT CTG TAT 
CAG TCT-3') in a SO-J-LI final PCR reaction mixturc consisting of 0.5 J..!,M 
reaction buffer (10 mM Tris H C I 8.3, 50 mM KCI, 1.5 mM MgCI), 200 J-LM 
dNTP, 2.5 U Taq-polymcrase (Biomcdica, Vicnna, Austria), and 5 J-Ll of 
cDNA teniplate. Samplcs wcre denatured at 94· C for 30 seconds, aod 
primcrs were annca lcd at 55°C for 30 seconds. Extcns ion waS at 72°C for 2 
min, and amplification was through 25 cycles. PCR. products were electro-
phoresed through a 2% agarose ge l and transferred onto a nylon mcmbran e 
(Nytran NY13N, Schl eicher & Schucll , Dassel, Germany). For Southern 
hybridization, 32p cnd-Iabcled scnse o ligonucletide probes (Ex4:S'-TTC 
CTA CAG CAC MC AAA TGT GAA TGC-3'; Ex6 : S'-AAA TCA GTT 
CGA GGA AAG GGA AAG-3'; Ex7: S' -AAG CATTTG TIT GTA CM 
GAT G-3 ' ) were lIsed at 106 cpm/ml. Figure lA illustrates the 10cali zatioJls 
of primers and probes within the VEGF cD NA. Hybridization proceeded in 
6 X SSC/O.O 'I% sodium dodecylsul fate (SDS) fo r 2 h at 52°C. SubscquentlY, 
membranes were washed with 2 X SSC/O.l 'X, SDS at 52°C for a.n additio nal 
2 hand cxposed to X-ray fi lm (Kodnk X-Al"t) in an X-ray cassette with 
intensifyin g scrccns at - 70°C for 24 and 72 h. 
Radioimmunoprecipitation ofVEGF For rad io immunoprccipica tioJ1, 
1 X 107 human kcratinocytcs werc incubatcd ill RPM 1- 1640 w ithout 
cyste ine or methioninc, supplementcd with 10% dialyzcd feta l bo.vine 
scrum , 0.4% bovinc pituitary cxtract. and 100 J-LC i/ ml cach o f ['5S1cystcioc 
and [35S1mcthioninc (New England Nuclcar G.m.b.H ., Vienna , Austria) in 
five T7S flasks in a tota l vo lumc of 50 1111. After 16 h, 2 ml complete 
RPMI-1640 was added, and cultures were allowed to procccd for a n 
additional 6 h. Radiolabcled culture supernatants were centrifuged twice :'It 
4500 rpm to rcmove rcsidual cc ll s before addition of 2 X lysis buffcr (2% 
Triton X -100, 100 mM T ri s-HC I pI-I 8.0, 300 mM NaCl, 4 mM EDTA, 3 
f.Lg/ m l Aprotin.in , 1.4 mM phenylmethylsulfonyl flu oride). To reducc 
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nonspecific binding, culturc supernatants were precleared w ith 2 ml packcd 
protcin A-Agarose beads (Boehringcr Mannhcim) and 60 J-LI o f norm"l 
rabbit serum for 6 h at 4· C. For radio immunoprecipitation , 25 ml of the 
supcrna tant was mixed with 10 J-LI of a rabbit anti- VEGF antiserum rai sed 
against a synthetic amino-term inal VEGF o ligopeptide [1 4] or with 10 J-LI of 
the preimmunc rabbit serum in the presence of either 2.5 fig recombinant 
human VEGF (R&D Systems, Abington Oxon, England) or 2.5 J.Lg bovine 
serum albumin and 100 J-LI pack cd pro te in A-Agarosc at 4°C fo r at least 8 h. 
The resu lting immul10precipi tates were washed sequentiall y in three bufFer 
solu tions,: buffer I (0.5% Triton-X, 20 mM Tris- I-I C I 8.0, 150 mM NaCI. 2 
mM EDTA, 1 % Aprotinin , 1 mM phcnylmethylsulfony l Auoride), buLrer II 
(samc as wash buffcr I, bur with 500 mM NaCI), and buffer III (60 mM 
T ri s-H Cl 6.8), and then processed furthcr fo r SDS-polyacrylamide gel 
e1ectrophorcsis (PAGE) undcr rcducing or non-reducing conditions in a 
12.5% homogcncous or in an 8% to 18'X) grad icnt polyacl}'lamide gel. After 
fixation, the gels were soaked in Auorograph.ic solution (AmpLi fy, Amcr-
sham In ternationa l pic, Buckinghamshire, England) and exposcd overnight 
to Kodak X-All... fi lms in an X-ra y cassette with intensifYing screens at 
-70°C. 
RESULTS 
Cultured Human Keratinocytes Express VEGF mRNA 
VEGF mRN A expression was d e tected in virtually all cell s when il1. 
sitll hybridization was performed on human keratinocytes in pri-
m ary c ulture u sing a 35S-labe le d VEGF-speciftc antisense riboprobe 
(Fig 2A,B). No specific hybridization cou ld be tound when the 
sense riboprobe was substituted (Fig 2C,D). 
Three VEGF mRNA Splice Variants Are Expressed by 
Human Keratinocytes in Primary Cultures The VEGF gen e 
conta ins e ig ht exons that are expressed in diffe re nt combin ation s by 
altemative splicing m ech anisms (Fig lB). To examine VEGF 
mRN A production by hum an keratinocytes, we performe d R T-
PCR u sing oligon ucleotide pl'imers situate d in the first exon and 
th e 3' un translated region of th e VEGF mR.N A (lVInlerinls f1l/d 
Methods). P C R produc ts w ere size-fi'actio na ted by agarose gel 
e lectrophoresis and ana lyzed by Southem hybridizatio n u sing 32p_ 
la be led VEGF o ligonu cleotide probes . As d e picted in Fig 3, 
amplification of cDN A derived from both primary keratinocytes 
and A431 cells resul ted in three bands of 520, 650, and 730 bp, a ll 
ofwhjch hybridized specifically with an o ligonucl eotide positione d 
in exon 4 iJl the V EGF gen e (Fig 3A). Because the known splice 




Figure 2. Human keratinocytes in primary cultures express VEGF 
,nRNA. {II s;t" hybridization offixed cul tured keratinocytcs was performed 
with 35S- labcled anti sense (A, B) and sense (C, 0) VEGF R.NA. Cell s were 
visualizcd by differential interferencc-contrast microscopy (A, C) o r by 
dark-fic ld view (B, 0). Bor, 50 ,.un. 
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Figure 3. Characterization of lORNA splice variants by RT-PCR 
and Southet:n analysis. R T-PCR was performed on RNA isolated from 
the primary keratinocytes in culture (Ialles 1) and from A431 cells (Ialles 2). 
For negativIC control (l alles 3), the eDNA template was omitted from the 
PCR reaction. Amplification products were hybridized with VEGF-specific 
oligonucleotide probes located in exon 4 (A), exon 7 (B), and exon 6 (C) . 
Numbers at the right are sizes of the DNA markers in base pairs; bars at the 
left indicate the position of the dilferent VEGF cDNAs. 
we rehybridized the sam e blots with o ligonucleotide probes that 
recognize these exons. The maj or 520-bp band lacked both exons 
(Fig 3B,C) , corresponding with what would be expected for 
VEGF 12 1 (Fig 1B), whereas the 730-bp band contained both exons 
6 and 7, characteristic of VEGF
,1l9 • Finally, the presence of exon 7 
and th e absence of exon 6 qualified the 650-bp product as cDNA 
corresponding with VEGF
,65 . 
HUinan Keratinocytes Release VEGF in the Culture Super-
natant To study the production of VEG F by human keratino-
cytes, we performed radioimmunoprecipitation on supernatants of 
[ 3 5S]cysteine- and [35S]methionine-labeled cells using a rabbit 
anti-VEGF antiserum (Materials and Methods). When immunopre-
cipita tes were analyzed by SDS-PAGE (12 .5% gel) under non-
reducing conditions, two molecu lar-weight forms of VEGF (ap-
proximately 45 and 58 kDa) were detected (Fig 4A, laue 4). When 
the same immunoprecipitates were analyzed on a 6% to 18% 
polyacl}rlamide gradient gel, the bands migrated faster, predictin g a 
molecular weight of approximately 38 to 46 kDa (data not shown). 
T hese bands could not be precipitated w hen excess unlabeled 
recombinant VEGF was added to reaction mixtures (Fig 4A, laue 
5). Under reducing conditions, three molecular-weight forms 
(approximate ly 24, 20, and 15 kDa) appeared (Fig 4B, (arle 4) . 
Specific immunoprecipitation was again blocked by adding excess 
unlabeled VEGF (Fig 4B, laue 5). N o specific reaction product 
could be observed with the preimmune rabbit serum (Fig 4A,B, 
lalles 2, 3) . 
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Figure 4. Analysis of keratinocytc-derived VEGF by radioimmu-
noprecipitation. l~adjoimmunoprecipitates were analyzed under 11 0n-
reduciJlg (A) and reducing (8) condi tions on a '1 2.5% polyacrylamide gel. 
Radioimmunoprecipitation was performed with either an anti-VEGF anti-
serum (lnltes 4, 5) o r the preimmul1e rabbit serum (10 lies 2. 3) in the presence 
of 2.5 [.Lg bovine serum albumin (l alles 2, 4) . or 2.5 [.Lg recombinant VEGF 
(Ialles 3, 5). Lalles 1 represent the molecular-weight markers. Ano/lls indicate 
the locations of 46-kl)" and 58-kDa VEGF proteins. 
DISCUSSION 
Angiogenesis, the formation of new blood vessels, sustain s the 
growth and development of aJ] normal tissues and plays a critical 
role in both wound healing and tumor surviv,il [22- 26]. Among the 
several factors known to promote angiogenesis through endothelial 
cell activation and growth [1, 27-29], VEGF has received special 
emphasis because in contrast to basic fibroblast growth factor 
(bFGF) and aFGF, its mitogenic activity is specific for vascular 
endothelial cells, and because it is a secreted product and therefore 
may act in a true paracrin e fashion. Although VEGF was charac-
terized initia11y as a product of tumor cells and tumor cell lines 
[1 ,3,13-1 6], including the epidermoid carcinoma line A431 [30], it 
is now known to be expressed by several normal tissues as well 
[1 ,16 -1 8]. R ecently, Brown et al [20] reported that keratinocytes in 
guinea pigs and rats express VEGF mRNA ill sitll during wound 
h ealing, and they noted that human keratinocytes secrete VEGF in 
primary cultures. We have now performed ill situ hybridization on 
proliferating human keratinocytes in primary cul tures and observed 
that virtually all cells express VEGF mRNA. Analysis of keratino-
cyte- and A431 cell-derived VEGF ml~As by RT-PCR yielded 
three amplification products, which were shown by Southem 
hybridization to correspond to the predominant three splice forms 
of VEGF [1 2,31,32]. No ampli.fication product correspondlilg with 
VEGF206 could be detected. 
Radioimmunoprecipitation of VEGF from the supematant of 
primary human keratinocytes and analysis by SDS-PAGE under 
non-reducing conditions revealed a distinct band of approximately 
58 kDa, in addition to the 45-kDa band that corresponds to the size 
d escribed for native VEGF [1]. Under reducing conditions, these 
baJlds gave rise to three proteins 0[24,20, and 15 kDa, confirming 
that keratinocyte-derived vEGF is secreted as a multimer. Because 
VEGF I B9 is thought not to be secreted [32]. these three subunits are 
m ost like ly the differentially glycosylated 121 aa and 165 aa forms, 
as has been described for VEGF derived from a guinea pig tumor 
cell lil1e [33]. N-deglycosylation experiments supported this as-
sumption because keratinocyte-derived VEGF produced a predom-
inant band with a m olecular weight of approximately 15 kDa, 
corresponding with the expected size of the VEGF,2, backbone 
protein (data not shown) . 
T he most obvious physiologic role proposed for keratinocyte-
derived VEGF is the support of angiogenesis during development 
and during wound healing. On the other hand, VEGF also must be 
examined for a pathogenic role in skin diseases characterized by 
neoangiogenesis and alterations of the epidermis. T he prototype for 
such a disease is psoriasis, in which, besides epidermal changes, 
del'mal micr,!vascular proliferation and remodeling are prominent. 
Not only might VEGF derived from keratinocytes modulate mito-
genic events in dermal endothelial cells, it also has a recognized 
capacity to alter vascular permeability, con'esponding with the 
excess endothelial gaps that characterize active lesions of psoriasis 
[34]. Finally, recent reports have indicated that VEGF exerts a 
cb e motactic effect on monocytes [35], an effect that can be found 
early in the development of psoriasis. T hus, VEGF must be 
included am ong the growing fami ly of keratinocyte-derived proin-
flammatory cytokines to be examined for a pathogeni c role in 
cutaneous inflammation . 
A lternatively, it is conceivable that VEGF not only plays a role in 
pathologic processes but also serves as a regulator of vascular 
homeostasis in normal skin. Support for this . assumption comes 
fi'o m our preliminary data showing that VEGF mRNA is e.\:pressed 
C()J1stitutively by keratinocytes of normal human skin ill sitll (not 
sh own) . T he regulation of VEGF production by keratinocytes ;'1 
II i 110, its bioavailability in the dermis, and its effects on dermal 
an g iogenesis are relevant subjects for further investigation. 
T his /IIork !lias SIIpp0I1ed b), gra llfs frOIll tile A IIstriall Sciellcc FOIllltiari'>II (Grallt 
P8466-MED, Grallt P01 437-MED). 
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